"Groundbreaking Study Reveals Optimal Treatment for Daytime Sleepiness"
A study conducted by researchers from McMaster University has found that solriamfetol is the most effective treatment for excessive daytime sleepiness (EDS) in individuals with obstructive sleep apnea (OSA), in addition to the standard positive airway pressure (PAP) mask treatment. The study, based on a comprehensive review of 14 clinical trials, suggests that solriamfetol, along with armodafinil-modafinil and pitolisant, can combat fatigue effectively. However, solriamfetol may raise blood pressure, which is a concern for OSA patients with cardiovascular issues. The researchers believe that these anti-fatigue medications could also be beneficial for related conditions such as chronic fatigue syndrome and long COVID.